var data={"title":"Treatment and prevention of Fusarium infection","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment and prevention of Fusarium infection</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/contributors\" class=\"contributor contributor_credentials\">Marcio Nucci, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/contributors\" class=\"contributor contributor_credentials\">Elias Anaissie, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/contributors\" class=\"contributor contributor_credentials\">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/contributors\" class=\"contributor contributor_credentials\">Anna R Thorner, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 07, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H472773620\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Fusarium</em> species cause a broad spectrum of infections in humans, including superficial infections such as keratitis and onychomycosis, as well as locally invasive and disseminated infections [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/1\" class=\"abstract_t\">1</a>]. Invasive and disseminated infections occur almost exclusively in severely immunocompromised patients, particularly among those with prolonged and profound neutropenia <span class=\"nowrap\">and/or</span> severe T cell immunodeficiency. Among patients with hematologic malignancy, the infection predominates during periods of neutropenia, typically among patients with leukemia receiving induction chemotherapy.</p><p><em>Fusarium</em> species may also cause allergic diseases, such as sinusitis in immunocompetent individuals [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/2\" class=\"abstract_t\">2</a>], and mycotoxicosis following ingestion of food contaminated by toxin-producing <em>Fusarium</em> species [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/3\" class=\"abstract_t\">3</a>]. <em>Fusarium</em> species are also important plant pathogens that cause various diseases on cereal grains [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/3\" class=\"abstract_t\">3</a>] and occasionally cause infection in animals [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/4\" class=\"abstract_t\">4</a>].</p><p>The treatment and prevention of fusariosis will be reviewed here. The mycology, pathogenesis, epidemiology, clinical manifestations, and diagnosis of fusariosis are discussed separately. (See <a href=\"topic.htm?path=mycology-pathogenesis-and-epidemiology-of-fusarium-infection\" class=\"medical medical_review\">&quot;Mycology, pathogenesis, and epidemiology of Fusarium infection&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-fusarium-infection\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of Fusarium infection&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H596312049\"><span class=\"h1\">SPECIES PREVALENCE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>More than 100 species of <em>Fusarium</em> have been identified but only a few cause infections in humans [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/5\" class=\"abstract_t\">5</a>]. <em>Fusarium solani</em> is the most frequent cause of invasive disease (in approximately half of all cases), followed by <em>F. oxysporum</em>, <em>F. verticillioides </em>(previously <em>F. moniliforme</em>), and <em>F. proliferatum </em>[<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/6\" class=\"abstract_t\">6</a>]. Other species that rarely cause infections in humans include <em>F. dimerum</em>, <em>F. chlamidosporum</em>, <em>F. sacchari</em>, <em>F. antophilum,</em> and others.</p><p>Molecular phylogenetic studies have revealed that these pathogens comprise species complexes. The clinical relevance of these species complexes remains to be determined.</p><p>Fusarial keratitis is most commonly caused by <em>F. solani</em> [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/7\" class=\"abstract_t\">7</a>], whereas fusarial onychomycosis is most commonly caused by <em>F. oxysporum</em> [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/8-10\" class=\"abstract_t\">8-10</a>].</p><p class=\"headingAnchor\" id=\"H346085910\"><span class=\"h1\">ANTIFUNGAL SUSCEPTIBILITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Fusarium</em> species are relatively resistant in vitro to most antifungal agents. Although antifungal susceptibility testing results have varied in different studies, the following general patterns have been observed [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/1,5,11-27\" class=\"abstract_t\">1,5,11-27</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most <em>Fusarium</em> isolates have higher amphotericin B minimum inhibitory concentrations (MICs) than do <em>Aspergillus</em> species.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Susceptibility to amphotericin B is usually higher than to the azoles <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>, <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>, and <a href=\"topic.htm?path=isavuconazole-isavuconazonium-sulfate-drug-information\" class=\"drug drug_general\">isavuconazole</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>F. solani</em> and <em>F. verticillioides </em>(previously <em>F. moniliforme</em>) have higher azole MICs than other <em>Fusarium</em> species.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>However, compared with <em>F. solani</em>, the MICs for <em>F. oxysporum</em> and <em>F. verticillioides</em> are lower for amphotericin B, <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>, and <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Susceptibility within a species complex may vary from one species to another [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/27\" class=\"abstract_t\">27</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Older azoles, such as <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> and <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, have high MICs to <em>Fusarium</em>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The echinocandins (<a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a>, <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a>, and <a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">anidulafungin</a>) lack activity against <em>Fusarium</em> spp.</p><p/><p>The clinical relevance of these in vitro data has not been established. Interpreting the MICs of antifungal agents for molds is difficult with no established breakpoints for defining susceptibility or resistance [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/6\" class=\"abstract_t\">6</a>]. Differences in testing methods are likely responsible for the differences in susceptibility testing results [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/14,16,17,19\" class=\"abstract_t\">14,16,17,19</a>]. Because of these limitations, we cannot recommend routine in vitro susceptibility testing. When testing is performed, the results must be interpreted with caution, and treatment decisions should be based mostly upon the individual patient's response to therapy. Acknowledging these limitations, the identification of <em>Fusarium</em> isolates to the species level may be clinically useful given the known variable susceptibility of different <em>Fusarium</em> spp to antifungal agents.</p><p>Certain antifungal agents, such as <a href=\"topic.htm?path=terbinafine-drug-information\" class=\"drug drug_general\">terbinafine</a> and the echinocandins, have little in vitro activity alone but appear synergistic with other antifungal agents in vitro when tested in combination. However, their role in the treatment of invasive disease is not clear. (See <a href=\"#H420415669\" class=\"local\">'Combination therapy'</a> below.)</p><p>Epidemiologic cutoff value (ECV) definitions for 1050 isolates of various species from laboratories from different countries have been reported [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/28\" class=\"abstract_t\">28</a>]. The ECV for <em>F. solani </em>species complex was 8 <span class=\"nowrap\">mcg/mL</span> for amphotericin B and 32 <span class=\"nowrap\">mcg/mL</span> for <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>, <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>, and <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>. For <em>F. oxysporum</em>,<em> </em>the ECV was 8 <span class=\"nowrap\">mcg/mL</span> for amphotericin B and posaconazole, 16 <span class=\"nowrap\">mcg/mL</span> for voriconazole, and 32 <span class=\"nowrap\">mcg/mL</span> for itraconazole. The use of ECVs and antifungal susceptibility testing is discussed in detail separately. (See <a href=\"topic.htm?path=antifungal-susceptibility-testing\" class=\"medical medical_review\">&quot;Antifungal susceptibility testing&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H420415640\"><span class=\"h1\">ANTIFUNGAL AGENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As discussed above, different <em>Fusarium</em> species exhibit variable in vitro susceptibility to antifungal agents, and the clinical relevance of these data is not known. This section describes what is known about the clinical use of antifungal agents for <em>Fusarium</em> infections; most data come from case reports and observational studies in immunocompromised patients with invasive fusariosis.</p><p>Treatment recommendations based upon the immune status of the host and the site(s) of infection are presented below. (See <a href=\"#H472773634\" class=\"local\">'Treatment'</a> below.)</p><p class=\"headingAnchor\" id=\"H420415648\"><span class=\"h2\">Amphotericin B</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lipid formulations of amphotericin B have been successful in the treatment of some patients and have been used most extensively for invasive fusariosis [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/29,30\" class=\"abstract_t\">29,30</a>]. In the Collaborative Exchange of Antifungal Research database, 28 of 3514 patients developed fusariosis and were treated with <a href=\"topic.htm?path=amphotericin-b-lipid-complex-drug-information\" class=\"drug drug_general\">amphotericin B lipid complex</a> either as primary or salvage therapy [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/30\" class=\"abstract_t\">30</a>]. Of the 26 evaluable patients, 12 (46 percent) were cured or improved, and 3 (12 percent) stabilized after receiving therapy. Patients with normal absolute neutrophil counts at the end of therapy had better outcomes than those who did not, regardless of neutrophil status at baseline.</p><p class=\"headingAnchor\" id=\"H420415655\"><span class=\"h2\">Azoles</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">Voriconazole</a> is fungicidal for filamentous fungi, including <em>Fusarium</em> spp, and is approved in many parts of the world, including the United States, Europe, and Brazil, for the treatment of <em>Fusarium</em> infections in patients who are not responding to or are intolerant of other therapies. This recommendation was based upon a series of only 11 patients [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/31\" class=\"abstract_t\">31</a>]. Additional publications have since extended the observations of the use of voriconazole among patients with fusariosis. These include a review of 102 cases [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/32\" class=\"abstract_t\">32</a>] and a composite review of 73 cases from the Pfizer database and the French National Reference Center for Mycoses database [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/33\" class=\"abstract_t\">33</a>]. In the latter study, the overall response rate (complete or partial) was 47 percent and 52 percent when data were limited to those patients who received at least five days of therapy [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/33\" class=\"abstract_t\">33</a>]. The response rate did not differ among different species. The most significant parameter that predicted success was resolution of neutropenia; a 63 percent response rate was observed among patients whose neutropenia resolved, compared with only 5 percent among patients who remained neutropenic. None of the four patients with brain lesions caused by <em>Fusarium</em> spp survived.</p><p>More recently, the outcomes of 233 cases of invasive fusariosis from 44 centers in 11 countries was analyzed [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/34\" class=\"abstract_t\">34</a>]. Compared with cases reported between 1985 and 2000, cases reported from 2001 to 2011 had a better 90-day survival rate (43 versus 22 percent). Differences in treatment practices between the earlier period and the later period included a reduction in the use of <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> and an increase in the use of <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> and combination therapy. During the later period, the 90-day survival was 60 percent with voriconazole treatment, 53 percent with a lipid formulation of amphotericin B, and 28 percent with amphotericin B deoxycholate.</p><p><a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">Posaconazole</a> possesses in vitro activity against <em>Fusarium</em> spp, although results differed among studies; as noted with <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>, the susceptibility pattern is species dependent [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/11\" class=\"abstract_t\">11</a>]. The clinical experience using posaconazole salvage therapy is somewhat limited. In a retrospective analysis, 21 patients with proven or probable invasive fusariosis who were not responding to or were intolerant of other therapies received oral posaconazole salvage therapy at 800 mg orally per day in divided doses [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/35\" class=\"abstract_t\">35</a>]. Most patients (76 percent) had an underlying hematologic malignancy. A 48 percent complete or partial response to posaconazole was seen. Case reports have also suggested that posaconazole is effective for fusariosis [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/36\" class=\"abstract_t\">36</a>]. On the other hand, cases of disseminated fusariosis have been reported in patients receiving posaconazole prophylaxis [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/37\" class=\"abstract_t\">37</a>].</p><p><a href=\"topic.htm?path=isavuconazole-isavuconazonium-sulfate-drug-information\" class=\"drug drug_general\">Isavuconazole</a> is a broad-spectrum azole approved for the treatment of invasive aspergillosis and mucormycosis. Clinical experience in the primary treatment of invasive fusariosis is limited; among nine reported cases, three had a complete or partial response [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/38\" class=\"abstract_t\">38</a>].</p><p>Because older azoles (eg, <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> and <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>) do not have activity against <em>Fusarium</em> species, they do not have a role in the treatment of invasive fusariosis [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/22,39\" class=\"abstract_t\">22,39</a>].</p><p class=\"headingAnchor\" id=\"H420415662\"><span class=\"h2\">Echinocandins</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The echinocandins (<a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a>, <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a>, <a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">anidulafungin</a>) should <strong>not</strong> be used to treat invasive infection with <em>Fusarium</em> spp because they lack activity against these pathogens [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/23\" class=\"abstract_t\">23</a>]. (See <a href=\"#H346085910\" class=\"local\">'Antifungal susceptibility'</a> above.)</p><p class=\"headingAnchor\" id=\"H420415669\"><span class=\"h2\">Combination therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Because of species-dependent variability in in vitro susceptibility profiles of <em>Fusarium</em> spp and the poor prognosis of fusariosis in immunocompromised hosts, particularly those with disseminated disease, some have recommended combination antifungal regimens initially in such settings in order to ensure activity of at least one agent [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/40,41\" class=\"abstract_t\">40,41</a>]. A small number of in vitro studies have suggested that certain antifungal combinations may be synergistic (eg, <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> plus <a href=\"topic.htm?path=terbinafine-drug-information\" class=\"drug drug_general\">terbinafine</a> [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/42,43\" class=\"abstract_t\">42,43</a>] or amphotericin B plus voriconazole [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/42,43\" class=\"abstract_t\">42,43</a>]), although possible antagonism remains a potential concern, particularly with the latter combination.</p><p>The clinical significance of these in vitro data is unclear. Single case reports have described successful outcomes using the following combinations: amphotericin B plus <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/40,44-46\" class=\"abstract_t\">40,44-46</a>], amphotericin B plus <a href=\"topic.htm?path=terbinafine-drug-information\" class=\"drug drug_general\">terbinafine</a> [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/47,48\" class=\"abstract_t\">47,48</a>], or amphotericin B plus <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a> [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/49\" class=\"abstract_t\">49</a>]. However, potential publication bias limits the usefulness of these findings. In a retrospective review of 73 patients with invasive fusariosis treated with voriconazole, 13 received another agent (<a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a>, terbinafine, caspofungin, or <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>) in combination with or immediately following voriconazole; the response rate among these patients was similar to that reported with voriconazole monotherapy [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/33\" class=\"abstract_t\">33</a>]. In an analysis of the outcomes of 233 cases of invasive fusariosis, a benefit of combination therapy was not observed, possibly because patients who received combination therapy were very sick with advanced disease and severe immunosuppression [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/34\" class=\"abstract_t\">34</a>].</p><p class=\"headingAnchor\" id=\"H472773634\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Because <em>Fusarium</em> species exhibit limited and species-dependent susceptibility to antifungal agents and because of the lack of randomized trials, the optimal treatment of fusariosis is not well established [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/50\" class=\"abstract_t\">50</a>]. Amphotericin B has been the most commonly used agent for invasive disease, but <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> is used with increasing frequency.</p><p class=\"headingAnchor\" id=\"H5520169\"><span class=\"h2\">Localized disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Localized disease, such as keratitis and onychomycosis, are the most common manifestations of <em>Fusarium</em> infection in immunocompetent patients.</p><p class=\"headingAnchor\" id=\"H346085004\"><span class=\"h3\">Keratitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Fusarial keratitis may develop following the traumatic inoculation of <em>Fusarium</em>-contaminated soil or plant material or related to poor hygiene practices in soft contact lens wearers. (See <a href=\"topic.htm?path=mycology-pathogenesis-and-epidemiology-of-fusarium-infection#H420413563\" class=\"medical medical_review\">&quot;Mycology, pathogenesis, and epidemiology of Fusarium infection&quot;, section on 'Keratitis'</a>.)</p><p>The treatment of <em>Fusarium</em> keratitis is challenging because of the limited and variable susceptibility of <em>Fusarium</em> spp to antifungal agents, the poor tissue penetration of topical antifungal agents, and the potential seriousness of infection by this pathogen, which can result in corneal perforation and even endophthalmitis. In one study, keratitis due to <em>Fusarium solani</em> was associated with longer time to cure and worse follow-up best-corrected visual acuity compared with non&ndash;<em>F.</em> <em>solani</em> cases [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/51\" class=\"abstract_t\">51</a>].</p><p>First-line therapy for fusarial keratitis includes a topical antifungal agent either alone or in combination with systemic antifungal medications. We favor a combination of topical plus systemic therapy in immunocompromised patients and in those with severe infections. <a href=\"topic.htm?path=natamycin-drug-information\" class=\"drug drug_general\">Natamycin</a> suspension (5 <span class=\"nowrap\">mg/mL)</span> has been the traditional drug of choice for topical therapy, although amphotericin B drops (1.5 <span class=\"nowrap\">mg/mL)</span> have also been used [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/7,52\" class=\"abstract_t\">7,52</a>]. Topical <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> is increasingly favored among ophthalmologists [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/53,54\" class=\"abstract_t\">53,54</a>]. However, one randomized trial comparing topical natamycin with topical voriconazole for the treatment of fungal keratitis (24.6 percent of which were caused by <em>Fusarium </em>spp) suggested that natamycin may be more effective in healing corneal ulcers and improving visual acuity [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/55\" class=\"abstract_t\">55</a>]. Topical agents should initially be applied hourly with subsequent modification based upon response.</p><p>The addition of systemic therapy with <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> is commonly used, particularly in severe cases [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/52,56\" class=\"abstract_t\">52,56</a>]. In hospitalized patients, the loading dose of voriconazole is 6 <span class=\"nowrap\">mg/kg</span> intravenously (IV) every 12 hours for two doses, followed by 4 <span class=\"nowrap\">mg/kg</span> IV every 12 hours. For outpatients, oral voriconazole may be given as a loading dose of 400 mg orally every 12 hours for two doses, followed by 200 mg orally twice daily. Oral <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> has been used successfully in three patients who did not respond to systemic <span class=\"nowrap\">and/or</span> topical voriconazole [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/57\" class=\"abstract_t\">57</a>]. Small case series have reported success in some patients, but not others, with the addition of intracorneal (intrastromal) injections of voriconazole in patients who responded poorly to topical and systemic therapy [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/58-60\" class=\"abstract_t\">58-60</a>].</p><p>The total duration of antifungal therapy depends upon the patient's response, which should be assessed frequently by ophthalmologic examinations. Many patients require several months of therapy. In a retrospective study of fungal keratitis, <em>Fusarium</em> was the most common pathogen, occurring in 29 of 78 eyes (37 percent) [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/61\" class=\"abstract_t\">61</a>]. The average duration of therapy was 81 days (range 20 days to 1 year). The time to healing, defined as resolution of infiltrate and epithelial healing, was a mean of 57 days but ranged from 8 to 300 days.</p><p>Patients who do not respond to antifungal therapy usually require corneal transplantation. Patients with keratitis should be managed by an ophthalmologist with expertise in corneal infections.</p><p>The management of endophthalmitis caused by molds is discussed separately. (See <a href=\"topic.htm?path=treatment-of-endophthalmitis-due-to-molds#H634314713\" class=\"medical medical_review\">&quot;Treatment of endophthalmitis due to molds&quot;, section on 'Treatment'</a>.)</p><p class=\"headingAnchor\" id=\"H346085011\"><span class=\"h3\">Onychomycosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Fusarium</em> onychomycosis is difficult to treat, with high failure rates even after long courses of systemic antifungal or topical therapy, with or without nail avulsion [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/62\" class=\"abstract_t\">62</a>]. Despite limited in vitro activity, oral <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> and <a href=\"topic.htm?path=terbinafine-drug-information\" class=\"drug drug_general\">terbinafine</a> are commonly used as therapy for fusarial onychomycosis and have been observed to be effective in immunocompetent patients in some [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/63-65\" class=\"abstract_t\">63-65</a>] but not all reports [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/66\" class=\"abstract_t\">66</a>]. The newer triazoles, <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> and <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>, have greater in vitro activity against <em>Fusarium</em> spp than itraconazole. We favor the use of oral voriconazole in immunocompromised patients with onychomycosis caused by <em>Fusarium</em> spp. Voriconazole is administered as a loading dose of 400 mg orally every 12 hours for two doses, followed by 200 mg orally twice daily. Adjunctive nail avulsion with topical amphotericin B can be used in patients who do not respond to systemic antifungal therapy, but it is usually avoided in severely immunocompromised patients. The infection often requires months of therapy and the duration depends on the patient's overall state of immunosuppression and the response to therapy. (See <a href=\"#H5520317\" class=\"local\">'Duration'</a> below.)</p><p>The management of onychomycosis in immunocompetent patients is discussed separately. (See <a href=\"topic.htm?path=onychomycosis-management\" class=\"medical medical_review\">&quot;Onychomycosis: Management&quot;</a> and <a href=\"topic.htm?path=onychomycosis-management#H782569850\" class=\"medical medical_review\">&quot;Onychomycosis: Management&quot;, section on 'Yeast and nondermatophyte mold onychomycosis'</a>.)</p><p class=\"headingAnchor\" id=\"H472773641\"><span class=\"h2\">Invasive disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Because <em>Fusarium</em> infections are almost always invasive in immunocompromised hosts and are often disseminated, treatment should be multifaceted; although systemic antifungal agents represent the cornerstone of therapy, surgical debridement of infected tissues <span class=\"nowrap\">and/or</span> removal of infected foreign bodies should be performed when possible. Therapy usually starts without knowing the infecting species because identification to the species level is typically performed only at reference laboratories, and results may not be rapidly available to the treating clinician.</p><p class=\"headingAnchor\" id=\"H472773663\"><span class=\"h3\">Choice of antifungal therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal treatment strategy of patients with fusariosis remains unclear because of the lack of clinical trials and the critical role that immune reconstitution plays in the outcome of this infection. Successful outcomes have been reported with various antifungal agents including <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/67\" class=\"abstract_t\">67</a>], <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a> [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/67\" class=\"abstract_t\">67</a>], <a href=\"topic.htm?path=amphotericin-b-lipid-complex-drug-information\" class=\"drug drug_general\">amphotericin B lipid complex</a> [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/30\" class=\"abstract_t\">30</a>], and the triazole antifungals, <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/31,33\" class=\"abstract_t\">31,33</a>], <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/35\" class=\"abstract_t\">35</a>], and <a href=\"topic.htm?path=isavuconazole-isavuconazonium-sulfate-drug-information\" class=\"drug drug_general\">isavuconazole</a> [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/38\" class=\"abstract_t\">38</a>]. Combination antifungal therapy has also been described in single case reports and a retrospective study, as discussed above. (See <a href=\"#H420415669\" class=\"local\">'Combination therapy'</a> above.)</p><p>A lipid formulation of amphotericin B (3 to 5 <span class=\"nowrap\">mg/kg</span> IV once daily) is usually the preferable first-line therapy. An alternative is <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> (6 <span class=\"nowrap\">mg/kg</span> IV every 12 hours for two doses, followed by 4 <span class=\"nowrap\">mg/kg</span> IV every 12 hours). A combination of a lipid formulation of amphotericin B and voriconazole is often used because of the variable susceptibility of <em>Fusarium</em> spp to antifungal agents and the need to ensure that at least one active antifungal agent is given [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/68\" class=\"abstract_t\">68</a>]. Combination therapy with a lipid formulation of amphotericin B and voriconazole should be considered in cases of severe immunosuppression <span class=\"nowrap\">and/or</span> severe disease or in patients with increasing skin lesions or persistently positive blood cultures while on monotherapy. We strongly discourage the use of <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> because it has more toxicities (especially nephrotoxicity) than the lipid formulations and because the response rate was lower compared with a lipid formulation of amphotericin B or voriconazole [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/34\" class=\"abstract_t\">34</a>]. (See <a href=\"topic.htm?path=pharmacology-of-amphotericin-b\" class=\"medical medical_review\">&quot;Pharmacology of amphotericin B&quot;</a> and <a href=\"topic.htm?path=amphotericin-b-nephrotoxicity\" class=\"medical medical_review\">&quot;Amphotericin B nephrotoxicity&quot;</a>.)</p><p>A switch from IV to oral therapy with either <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> (200 to 300 mg orally twice daily) or <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> delayed-release tablets (300 mg orally once daily) may be considered upon achievement of a significant response, provided that the patient is compliant and is able to absorb oral medications. Monitoring serum drug concentration is recommended during oral therapy. This is discussed in detail separately. (See <a href=\"topic.htm?path=pharmacology-of-azoles#H28\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Voriconazole'</a> and <a href=\"topic.htm?path=pharmacology-of-azoles#H30\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Posaconazole'</a>.)</p><p class=\"headingAnchor\" id=\"H5520317\"><span class=\"h3\">Duration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The duration of antifungal therapy depends upon the site and extent of the infection, the patient's underlying disease and immune status, the need for continuous immunosuppression, and the response to therapy. The most important factor in outcome is resolution of neutropenia. Antifungal therapy is generally continued until all signs and symptoms of the infection have resolved, radiographic abnormalities have stabilized, and significant immune reconstitution has occurred. For severely immunosuppressed patients, antifungal therapy may continue for months or longer in some cases.</p><p class=\"headingAnchor\" id=\"H472773691\"><span class=\"h3\">Adjunctive therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Because a recovering immune system is essential for the successful outcome of fusariosis, every effort should be made to enhance immunity; this includes decreasing the dose of immunosuppressants when possible and the use of adjunctive immunotherapy, such as granulocyte or granulocyte-macrophage colony-stimulating factors (G-CSF or GM-CSF), G-CSF&ndash; or G-CSF plus <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a>&ndash;stimulated granulocyte transfusions, or interferon-gamma. The efficacy of these therapies for fusariosis has not been established [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/69,70\" class=\"abstract_t\">69,70</a>]. A single-center series of 11 patients with invasive fusariosis treated with antifungal agents and G-CSF plus dexamethasone&ndash;stimulated granulocyte transfusions reported a 73 percent 90-day survival. As expected, all survivors had neutrophil recovery [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/71\" class=\"abstract_t\">71</a>].</p><p>Additional strategies include surgical debridement of infected tissues (eg, sinuses, soft tissues, lung nodules) [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/72\" class=\"abstract_t\">72</a>], particularly in immunocompromised patients with localized disease, and removal of central venous catheters in patients with possible catheter-related fusariosis [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/73\" class=\"abstract_t\">73</a>].</p><p class=\"headingAnchor\" id=\"H472773698\"><span class=\"h1\">PREVENTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Because of the poor prognosis associated with fusariosis and the limited susceptibility of <em>Fusarium</em> species to antifungal agents, preventing this infection is important, when possible.</p><p class=\"headingAnchor\" id=\"H524570891\"><span class=\"h2\">Primary prophylaxis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>General preventive measures that should be employed in patients at significant risk of invasive fusariosis, such as patients with hematologic malignancies undergoing induction chemotherapy or hematopoietic cell transplantation (HCT), include [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/1,74-76\" class=\"abstract_t\">1,74-76</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Avoidance of activities associated with skin breakdown</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Avoidance of contact of areas of skin breakdown with tap water</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Careful examination for and treatment of onychomycosis, interdigital intertrigo, and paronychia and surgical debridement of infected wounds prior to commencing anticancer therapies (see <a href=\"#H346085011\" class=\"local\">'Onychomycosis'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Delaying severely immunosuppressive therapies until areas of skin breakdown are healed, when possible</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Following appropriate air and water precautions during periods at risk &ndash; These include use of a high-efficiency particulate air filter and positive pressure isolation rooms, avoiding contact with reservoirs of <em>Fusarium </em>spp, such as tap water, and having showers cleaned thoroughly prior to use by high-risk patients. (See <a href=\"topic.htm?path=prophylaxis-of-infection-during-chemotherapy-induced-neutropenia-in-high-risk-adults#H875811313\" class=\"medical medical_review\">&quot;Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults&quot;, section on 'Infection control and general precautions'</a>.)</p><p/><p>One study showed that patients with hematologic malignancies who had interdigital intertrigo <span class=\"nowrap\">and/or</span> onychomycosis at the time of hospital admission and who had cultures of such lesions showing <em>Fusarium</em> spp were at increased risk for development of invasive disease [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/77\" class=\"abstract_t\">77</a>]. In a subsequent study, of five patients who had positive cultures of skin lesions and who did not receive prophylaxis, four developed invasive fusariosis [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/78\" class=\"abstract_t\">78</a>]. By contrast, none of six patients who received prophylaxis with <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> or <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> developed invasive fusariosis, a difference that was statistically significant.</p><p>Considering the high mortality rate associated with invasive fusariosis, we also favor the following approach for patients at significant risk of invasive fusariosis:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A thorough dermatologic examination of the extremities upon admission</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Culture of any suspicious lesion (especially interdigital intertrigo or onychomycosis), and</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary prophylaxis with <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> or <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> in patients with positive cultures</p><p/><p>Since fungi may take a few days to grow in cultures, we initiate prophylaxis if hyaline hyphae are observed on direct microscopy and adjust prophylaxis a few days later, when cultures confirm (or exclude) the diagnosis of superficial fusariosis.</p><p><a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">Posaconazole</a> delayed-release tablets should be given as a loading dose of 300 mg (three 100 mg tablets) every 12 hours on the first day, followed by a maintenance dose of 300 mg (three 100 mg tablets) daily starting on the second day.</p><p><a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">Voriconazole</a> is administered as a loading dose of 400 mg orally every 12 hours for two doses, followed by 200 mg orally twice daily.</p><p class=\"headingAnchor\" id=\"H524570898\"><span class=\"h2\">Secondary prophylaxis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients who had a prior episode of fusariosis, secondary antifungal prophylaxis should be given to prevent relapse of infection during periods of increased immunosuppression. Secondary prophylaxis should be given when the patient receives chemotherapy, undergoes HCT, or when immunosuppression is significantly increased for the management of graft-versus-host disease (GVHD). Among patients with a history of invasive <em>Fusarium</em> infection, the following measures should be taken [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/1\" class=\"abstract_t\">1</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Evaluation of residual infection prior to starting immunosuppressive therapy: blood cultures, imaging with computed tomography, others as indicated</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prophylaxis with an antifungal agent active against the <em>Fusarium </em>species previously isolated (<a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>, <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>, or a lipid formulation of amphotericin B) (see <a href=\"#H472773663\" class=\"local\">'Choice of antifungal therapy'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Application of less immunosuppressive therapies when possible (eg, dose reduction of the antineoplastic regimen, reduced intensity rather than myeloablative conditioning regimen for HCT)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Careful selection of donors in allogeneic HCT to decrease the immunosuppressive effects of GVHD, graft failure, or cytomegalovirus reactivation</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Consideration of granulocyte colony-stimulating factor plus dexamethasone-elicited granulocyte transfusions during periods of expected neutropenia [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/69,70\" class=\"abstract_t\">69,70</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Documentation of GVHD before empirical therapy with glucocorticoids, when possible, and prompt therapy of GVHD with the lowest immunosuppressive regimen possible and a careful approach to glucocorticoid tapering</p><p/><p class=\"headingAnchor\" id=\"H5519506\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The prognosis of fusariosis is directly related to the patient's immune status, with very high mortality rates in persistently immunocompromised patients. The overall mortality rate from disseminated <em>Fusarium</em> infection is 60 to 80 percent [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/1,29,79-81\" class=\"abstract_t\">1,29,79-81</a>]. In a series of 84 patients with fusariosis and an underlying hematologic malignancy, the 30- and 90-day survival rates were 50 and 21 percent, respectively [<a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/67\" class=\"abstract_t\">67</a>]. Persistent neutropenia and recent glucocorticoid therapy were the only independent factors associated with poor outcome; no patient who had adverse prognostic factors survived, whereas the survival rate was 67 percent among patients who had neither of these factors.</p><p class=\"headingAnchor\" id=\"H472773705\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Fusarium</em> species cause a broad spectrum of infections in humans including superficial infections, such as keratitis and onychomycosis, as well as locally invasive and disseminated infections. Invasive and disseminated infections occur almost exclusively in severely immunocompromised patients. (See <a href=\"#H472773620\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Fusarium solani</em> is the most frequent cause of invasive disease, causing approximately 50 percent of cases, followed by <em>F. oxysporum</em>, <em>F. verticillioides</em> (previously <em>F. moniliforme</em>), and <em>F. proliferatum</em>. Fusarial keratitis is most commonly caused by <em>F. solani</em>, whereas fusarial onychomycosis is most commonly caused by <em>F. oxysporum</em>. (See <a href=\"#H596312049\" class=\"local\">'Species prevalence'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Fusarium</em> species usually exhibit high minimum inhibitory concentrations (MICs) to most antifungal agents, with <em>F. solani</em> showing higher MICs than other <em>Fusarium</em> species. (See <a href=\"#H346085910\" class=\"local\">'Antifungal susceptibility'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients suspected of having <em>Fusarium</em> keratitis should be evaluated and treated urgently. Treatment usually involves a combination of topical and systemic antifungal therapy. For patients with <em>Fusarium</em> keratitis, we suggest initial therapy with a topical antifungal agent in combination with systemic <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Appropriate topical agents include <a href=\"topic.htm?path=natamycin-drug-information\" class=\"drug drug_general\">natamycin</a>, voriconazole, and amphotericin B. Topical agents should be used every hour initially. (See <a href=\"#H346085004\" class=\"local\">'Keratitis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For immunocompromised patients with <em>Fusarium</em> onychomycosis, we suggest <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H346085011\" class=\"local\">'Onychomycosis'</a> above and <a href=\"#H524570891\" class=\"local\">'Primary prophylaxis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Immunocompromised patients with invasive fusariosis require aggressive antifungal therapy. In such patients, we suggest initial therapy with a lipid formulation of amphotericin B or <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Combination therapy with a lipid formulation of amphotericin B and voriconazole should be considered in cases of severe immunosuppression <span class=\"nowrap\">and/or</span> severe disease. The dosing of lipid formulations of amphotericin B is 3 to 5 <span class=\"nowrap\">mg/kg</span> intravenously (IV) once daily, and the dosing of voriconazole is 6 <span class=\"nowrap\">mg/kg</span> IV every 12 hours for two doses, followed by 4 <span class=\"nowrap\">mg/kg</span> IV every 12 hours. (See <a href=\"#H472773663\" class=\"local\">'Choice of antifungal therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Disseminated <em>Fusarium</em> infections are associated with high mortality rates. The prognosis of fusariosis is directly related to the patient's immune status, with high mortality rates in persistently immunosuppressed patients, especially those who remain neutropenic. (See <a href=\"#H5519506\" class=\"local\">'Prognosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients at significant risk of invasive fusariosis, such as those with hematologic malignancies undergoing induction chemotherapy or hematopoietic cell transplantation (HCT), we suggest a thorough dermatologic examination of the extremities upon admission, culture of any suspicious lesion (especially interdigital intertrigo or onychomycosis), and primary prophylaxis with <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> or <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> in patients with positive cultures for Fusarium spp (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Other preventive measures are discussed above. (See <a href=\"#H524570891\" class=\"local\">'Primary prophylaxis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients who had a prior episode of fusariosis, we suggest secondary antifungal prophylaxis to prevent relapse of infection during periods of increased immunosuppression (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Secondary prophylaxis should be given when the patient receives chemotherapy, undergoes HCT, or when immunosuppression is significantly increased for the management of graft-versus-host disease. (See <a href=\"#H524570898\" class=\"local\">'Secondary prophylaxis'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/1\" class=\"nounderline abstract_t\">Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20:695.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/2\" class=\"nounderline abstract_t\">Wickern GM. Fusarium allergic fungal sinusitis. J Allergy Clin Immunol 1993; 92:624.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/3\" class=\"nounderline abstract_t\">Nelson PE, Dignani MC, Anaissie EJ. Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev 1994; 7:479.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/4\" class=\"nounderline abstract_t\">Evans J, Levesque D, de Lahunta A, Jensen HE. Intracranial fusariosis: a novel cause of fungal meningoencephalitis in a dog. Vet Pathol 2004; 41:510.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/5\" class=\"nounderline abstract_t\">Alastruey-Izquierdo A, Cuenca-Estrella M, Monz&oacute;n A, et al. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother 2008; 61:805.</a></li><li class=\"breakAll\">Torres HA, Kontoyiannis DP. Hyalohyphomycoses (Hyaline Moulds). In: Essentials of Clinical Mycology, Second edition, Kauffman C, Pappas PG, Sobel JD (Eds), Springer, New York 2011. p.281.</li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/7\" class=\"nounderline abstract_t\">D&oacute;czi I, Gyetvai T, Kredics L, Nagy E. Involvement of Fusarium spp. in fungal keratitis. Clin Microbiol Infect 2004; 10:773.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/8\" class=\"nounderline abstract_t\">Brilhante RS, Cordeiro RA, Medrano DJ, et al. Onychomycosis in Cear&aacute; (Northeast Brazil): epidemiological and laboratory aspects. Mem Inst Oswaldo Cruz 2005; 100:131.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/9\" class=\"nounderline abstract_t\">Godoy P, Nunes E, Silva V, et al. Onychomycosis caused by Fusarium solani and Fusarium oxysporum in S&atilde;o Paulo, Brazil. Mycopathologia 2004; 157:287.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/10\" class=\"nounderline abstract_t\">Ninet B, Jan I, Bontems O, et al. Molecular identification of Fusarium species in onychomycoses. Dermatology 2005; 210:21.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/11\" class=\"nounderline abstract_t\">Torres HA, Hachem RY, Chemaly RF, et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005; 5:775.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/12\" class=\"nounderline abstract_t\">Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006; 50:917.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/13\" class=\"nounderline abstract_t\">Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20:121.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/14\" class=\"nounderline abstract_t\">Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, et al. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother 2002; 46:3298.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/15\" class=\"nounderline abstract_t\">Arikan S, Lozano-Chiu M, Paetznick V, et al. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol 1999; 37:3946.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/16\" class=\"nounderline abstract_t\">Espinel-Ingroff A, Chaturvedi V, Fothergill A, Rinaldi MG. Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J Clin Microbiol 2002; 40:3776.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/17\" class=\"nounderline abstract_t\">Meletiadis J, Meis JF, Mouton JW, et al. Comparison of NCCLS and 3-(4,5-dimethyl-2-Thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. J Clin Microbiol 2000; 38:2949.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/18\" class=\"nounderline abstract_t\">Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42:4419.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/19\" class=\"nounderline abstract_t\">Szekely A, Johnson EM, Warnock DW. Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of molds. J Clin Microbiol 1999; 37:1480.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/20\" class=\"nounderline abstract_t\">Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50:2009.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/21\" class=\"nounderline abstract_t\">Tortorano AM, Prigitano A, Dho G, et al. Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy. Antimicrob Agents Chemother 2008; 52:2683.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/22\" class=\"nounderline abstract_t\">Speeleveld E, Gordts B, Van Landuyt HW, et al. Susceptibility of clinical isolates of Fusarium to antifungal drugs. Mycoses 1996; 39:37.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/23\" class=\"nounderline abstract_t\">Cornely OA, Schmitz K, Aisenbrey S. The first echinocandin: caspofungin. Mycoses 2002; 45 Suppl 3:56.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/24\" class=\"nounderline abstract_t\">Debourgogne A, de Hoog S, Lozniewski A, Machouart M. Amphotericin B and voriconazole susceptibility profiles for the Fusarium solani species complex: comparison between the E-test and CLSI M38-A2 microdilution methodology. Eur J Clin Microbiol Infect Dis 2012; 31:615.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/25\" class=\"nounderline abstract_t\">Tortorano AM, Prigitano A, Esposto MC, et al. European Confederation of Medical Mycology (ECMM) epidemiological survey on invasive infections due to Fusarium species in Europe. Eur J Clin Microbiol Infect Dis 2014; 33:1623.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/26\" class=\"nounderline abstract_t\">Guinea J, Pel&aacute;ez T, Recio S, et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008; 52:1396.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/27\" class=\"nounderline abstract_t\">Al-Hatmi AM, van Diepeningen AD, Curfs-Breuker I, et al. Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex. J Antimicrob Chemother 2015; 70:1068.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/28\" class=\"nounderline abstract_t\">Espinel-Ingroff A, Colombo AL, Cordoba S, et al. International Evaluation of MIC Distributions and Epidemiological Cutoff Value (ECV) Definitions for Fusarium Species Identified by Molecular Methods for the CLSI Broth Microdilution Method. Antimicrob Agents Chemother 2016; 60:1079.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/29\" class=\"nounderline abstract_t\">Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90:999.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/30\" class=\"nounderline abstract_t\">Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 2005; 40 Suppl 6:S401.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/31\" class=\"nounderline abstract_t\">Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/32\" class=\"nounderline abstract_t\">Stanzani M, Tumietto F, Vianelli N, Baccarani M. Update on the treatment of disseminated fusariosis: Focus on voriconazole. Ther Clin Risk Manag 2007; 3:1165.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/33\" class=\"nounderline abstract_t\">Lortholary O, Obenga G, Biswas P, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother 2010; 54:4446.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/34\" class=\"nounderline abstract_t\">Nucci M, Marr KA, Vehreschild MJ, et al. Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect 2014; 20:580.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/35\" class=\"nounderline abstract_t\">Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42:1398.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/36\" class=\"nounderline abstract_t\">Herbrecht R, Kessler R, Kravanja C, et al. Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient. J Heart Lung Transplant 2004; 23:1451.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/37\" class=\"nounderline abstract_t\">Bose P, Parekh HD, Holter JL, Greenfield RA. Disseminated fusariosis occurring in two patients despite posaconazole prophylaxis. J Clin Microbiol 2011; 49:1674.</a></li><li class=\"breakAll\">Cornely OA, Ostrosky-Zeichner L, Rahav G, et al. Outcomes in patients with invasive mold disease caused by Fusarium or Scedosporium spp treated with isavuconazole: experience from the VITAL and SECURE trials. (Abstract M-1760) In: Program and abstracts of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC 2014.</li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/39\" class=\"nounderline abstract_t\">Pujol I, Guarro J, Gen&eacute; J, Sala J. In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. J Antimicrob Chemother 1997; 39:163.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/40\" class=\"nounderline abstract_t\">Ho DY, Lee JD, Rosso F, Montoya JG. Treating disseminated fusariosis: amphotericin B, voriconazole or both? Mycoses 2007; 50:227.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/41\" class=\"nounderline abstract_t\">Vazquez JA. Clinical practice: combination antifungal therapy for mold infections: much ado about nothing? Clin Infect Dis 2008; 46:1889.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/42\" class=\"nounderline abstract_t\">C&oacute;rdoba S, Rodero L, Vivot W, et al. In vitro interactions of antifungal agents against clinical isolates of Fusarium spp. Int J Antimicrob Agents 2008; 31:171.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/43\" class=\"nounderline abstract_t\">Ortoneda M, Capilla J, Javier Pastor F, et al. In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn Microbiol Infect Dis 2004; 48:69.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/44\" class=\"nounderline abstract_t\">Durand-Joly I, Alfandari S, Benchikh Z, et al. Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia. J Clin Microbiol 2003; 41:4898.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/45\" class=\"nounderline abstract_t\">Guzman-Cottrill JA, Zheng X, Chadwick EG. Fusarium solani endocarditis successfully treated with liposomal amphotericin B and voriconazole. Pediatr Infect Dis J 2004; 23:1059.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/46\" class=\"nounderline abstract_t\">Tezcan G, Ozhak-Baysan B, Alastruey-Izquierdo A, et al. Disseminated fusariosis caused by Fusarium verticillioides in an acute lymphoblastic leukemia patient after allogeneic hematopoietic stem cell transplantation. J Clin Microbiol 2009; 47:278.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/47\" class=\"nounderline abstract_t\">Rothe A, Seibold M, Hoppe T, et al. Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann Hematol 2004; 83:394.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/48\" class=\"nounderline abstract_t\">Neuburger S, Massenkeil G, Seibold M, et al. Successful salvage treatment of disseminated cutaneous fusariosis with liposomal amphotericin B and terbinafine after allogeneic stem cell transplantation. Transpl Infect Dis 2008; 10:290.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/49\" class=\"nounderline abstract_t\">Makowsky MJ, Warkentin DI, Savoie ML. Caspofungin and amphotericin B for disseminated Fusarium verticillioides in leukemia. Ann Pharmacother 2005; 39:1365.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/50\" class=\"nounderline abstract_t\">Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect 2004; 10 Suppl 1:67.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/51\" class=\"nounderline abstract_t\">Oechsler RA, Feilmeier MR, Miller D, et al. Fusarium keratitis: genotyping, in vitro susceptibility and clinical outcomes. Cornea 2013; 32:667.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/52\" class=\"nounderline abstract_t\">Alfonso EC, Cantu-Dibildox J, Munir WM, et al. Insurgence of Fusarium keratitis associated with contact lens wear. Arch Ophthalmol 2006; 124:941.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/53\" class=\"nounderline abstract_t\">Bunya VY, Hammersmith KM, Rapuano CJ, et al. Topical and oral voriconazole in the treatment of fungal keratitis. Am J Ophthalmol 2007; 143:151.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/54\" class=\"nounderline abstract_t\">Hariprasad SM, Mieler WF, Lin TK, et al. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol 2008; 92:871.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/55\" class=\"nounderline abstract_t\">Sharma S, Das S, Virdi A, et al. Re-appraisal of topical 1% voriconazole and 5% natamycin in the treatment of fungal keratitis in a randomised trial. Br J Ophthalmol 2015; 99:1190.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/56\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Fusarium keratitis--multiple states, 2006. MMWR Morb Mortal Wkly Rep 2006; 55:400.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/57\" class=\"nounderline abstract_t\">Tu EY, McCartney DL, Beatty RF, et al. Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592). Am J Ophthalmol 2007; 143:222.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/58\" class=\"nounderline abstract_t\">Sharma N, Agarwal P, Sinha R, et al. Evaluation of intrastromal voriconazole injection in recalcitrant deep fungal keratitis: case series. Br J Ophthalmol 2011; 95:1735.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/59\" class=\"nounderline abstract_t\">Siatiri H, Daneshgar F, Siatiri N, Khodabande A. The effects of intrastromal voriconazole injection and topical voriconazole in the treatment of recalcitrant Fusarium keratitis. Cornea 2011; 30:872.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/60\" class=\"nounderline abstract_t\">Kalaiselvi G, Narayana S, Krishnan T, Sengupta S. Intrastromal voriconazole for deep recalcitrant fungal keratitis: a case series. Br J Ophthalmol 2015; 99:195.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/61\" class=\"nounderline abstract_t\">Yildiz EH, Abdalla YF, Elsahn AF, et al. Update on fungal keratitis from 1999 to 2008. Cornea 2010; 29:1406.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/62\" class=\"nounderline abstract_t\">Tosti A, Piraccini BM, Lorenzi S, Iorizzo M. Treatment of nondermatophyte mold and Candida onychomycosis. Dermatol Clin 2003; 21:491.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/63\" class=\"nounderline abstract_t\">Hattori N, Shirai A, Sugiura Y, et al. Onychomycosis caused by Fusarium proliferatum. Br J Dermatol 2005; 153:647.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/64\" class=\"nounderline abstract_t\">Gupta AK, Baran R, Summerbell RC. Fusarium infections of the skin. Curr Opin Infect Dis 2000; 13:121.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/65\" class=\"nounderline abstract_t\">Guilhermetti E, Takahachi G, Shinobu CS, Svidzinski TI. Fusarium spp. as agents of onychomycosis in immunocompetent hosts. Int J Dermatol 2007; 46:822.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/66\" class=\"nounderline abstract_t\">Baudraz-Rosselet F, Ruffieux C, Lurati M, et al. Onychomycosis insensitive to systemic terbinafine and azole treatments reveals non-dermatophyte moulds as infectious agents. Dermatology 2010; 220:164.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/67\" class=\"nounderline abstract_t\">Nucci M, Anaissie EJ, Queiroz-Telles F, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003; 98:315.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/68\" class=\"nounderline abstract_t\">McCarthy M, Rosengart A, Schuetz AN, et al. Mold infections of the central nervous system. N Engl J Med 2014; 371:150.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/69\" class=\"nounderline abstract_t\">Dignani MC, Anaissie EJ, Hester JP, et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia 1997; 11:1621.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/70\" class=\"nounderline abstract_t\">Hennequin C, Benkerrou M, Gaillard JL, et al. Role of granulocyte colony-stimulating factor in the management of infection with Fusarium oxysporum in a neutropenic child. Clin Infect Dis 1994; 18:490.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/71\" class=\"nounderline abstract_t\">Kadri SS, Remy KE, Strich JR, et al. Role of granulocyte transfusions in invasive fusariosis: systematic review and single-center experience. Transfusion 2015; 55:2076.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/72\" class=\"nounderline abstract_t\">Lupinetti FM, Giller RH, Trigg ME. Operative treatment of Fusarium fungal infection of the lung. Ann Thorac Surg 1990; 49:991.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/73\" class=\"nounderline abstract_t\">Velasco E, Martins CA, Nucci M. Successful treatment of catheter-related fusarial infection in immunocompromised children. Eur J Clin Microbiol Infect Dis 1995; 14:697.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/74\" class=\"nounderline abstract_t\">Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002; 35:909.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/75\" class=\"nounderline abstract_t\">Anaissie EJ, Kuchar RT, Rex JH, et al. Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis 2001; 33:1871.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/76\" class=\"nounderline abstract_t\">Anaissie EJ, Stratton SL, Dignani MC, et al. Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds. Clin Infect Dis 2002; 35:E86.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/77\" class=\"nounderline abstract_t\">Varon AG, Nouer SA, Barreiros G, et al. Superficial skin lesions positive for Fusarium are associated with subsequent development of invasive fusariosis. J Infect 2014; 68:85.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/78\" class=\"nounderline abstract_t\">Varon AG, Nou&eacute;r SA, Barreiros G, et al. Antimold Prophylaxis May Reduce the Risk of Invasive Fusariosis in Hematologic Patients with Superficial Skin Lesions with Positive Culture for Fusarium. Antimicrob Agents Chemother 2016; 60:7290.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/79\" class=\"nounderline abstract_t\">Martino P, Gastaldi R, Raccah R, Girmenia C. Clinical patterns of Fusarium infections in immunocompromised patients. J Infect 1994; 28 Suppl 1:7.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/80\" class=\"nounderline abstract_t\">Gamis AS, Gudnason T, Giebink GS, Ramsay NK. Disseminated infection with Fusarium in recipients of bone marrow transplants. Rev Infect Dis 1991; 13:1077.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-and-prevention-of-fusarium-infection/abstract/81\" class=\"nounderline abstract_t\">Venditti M, Micozzi A, Gentile G, et al. Invasive Fusarium solani infections in patients with acute leukemia. Rev Infect Dis 1988; 10:653.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 15674 Version 18.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H472773705\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H472773620\" id=\"outline-link-H472773620\">INTRODUCTION</a></li><li><a href=\"#H596312049\" id=\"outline-link-H596312049\">SPECIES PREVALENCE</a></li><li><a href=\"#H346085910\" id=\"outline-link-H346085910\">ANTIFUNGAL SUSCEPTIBILITY</a></li><li><a href=\"#H420415640\" id=\"outline-link-H420415640\">ANTIFUNGAL AGENTS</a><ul><li><a href=\"#H420415648\" id=\"outline-link-H420415648\">Amphotericin B</a></li><li><a href=\"#H420415655\" id=\"outline-link-H420415655\">Azoles</a></li><li><a href=\"#H420415662\" id=\"outline-link-H420415662\">Echinocandins</a></li><li><a href=\"#H420415669\" id=\"outline-link-H420415669\">Combination therapy</a></li></ul></li><li><a href=\"#H472773634\" id=\"outline-link-H472773634\">TREATMENT</a><ul><li><a href=\"#H5520169\" id=\"outline-link-H5520169\">Localized disease</a><ul><li><a href=\"#H346085004\" id=\"outline-link-H346085004\">- Keratitis</a></li><li><a href=\"#H346085011\" id=\"outline-link-H346085011\">- Onychomycosis</a></li></ul></li><li><a href=\"#H472773641\" id=\"outline-link-H472773641\">Invasive disease</a><ul><li><a href=\"#H472773663\" id=\"outline-link-H472773663\">- Choice of antifungal therapy</a></li><li><a href=\"#H5520317\" id=\"outline-link-H5520317\">- Duration</a></li><li><a href=\"#H472773691\" id=\"outline-link-H472773691\">- Adjunctive therapies</a></li></ul></li></ul></li><li><a href=\"#H472773698\" id=\"outline-link-H472773698\">PREVENTION</a><ul><li><a href=\"#H524570891\" id=\"outline-link-H524570891\">Primary prophylaxis</a></li><li><a href=\"#H524570898\" id=\"outline-link-H524570898\">Secondary prophylaxis</a></li></ul></li><li><a href=\"#H5519506\" id=\"outline-link-H5519506\">PROGNOSIS</a></li><li><a href=\"#H472773705\" id=\"outline-link-H472773705\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=amphotericin-b-nephrotoxicity\" class=\"medical medical_review\">Amphotericin B nephrotoxicity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antifungal-susceptibility-testing\" class=\"medical medical_review\">Antifungal susceptibility testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-fusarium-infection\" class=\"medical medical_review\">Clinical manifestations and diagnosis of Fusarium infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mycology-pathogenesis-and-epidemiology-of-fusarium-infection\" class=\"medical medical_review\">Mycology, pathogenesis, and epidemiology of Fusarium infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=onychomycosis-management\" class=\"medical medical_review\">Onychomycosis: Management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacology-of-amphotericin-b\" class=\"medical medical_review\">Pharmacology of amphotericin B</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacology-of-azoles\" class=\"medical medical_review\">Pharmacology of azoles</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prophylaxis-of-infection-during-chemotherapy-induced-neutropenia-in-high-risk-adults\" class=\"medical medical_review\">Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-endophthalmitis-due-to-molds\" class=\"medical medical_review\">Treatment of endophthalmitis due to molds</a></li></ul></div></div>","javascript":null}